Travere Therapeutics, Inc. revenue for the last year amounted to 145.24 M USD, the most of which — 98.33 M USD — came from its highest performing source at the moment, Tiopronin Products, the year earlier bringing 97.97 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Travere Therapeutics, Inc. 127.54 M USD, and the year before that — 200.53 M USD.